Furthermore, a recent case report has documented clinical activity of the tropomyosin receptor kinase (TRK) inhibitor lacrotrectinib in ETV6-NTRK3 associated Ph-like ALL [51], and an active phase II clinical trial is evaluating this agent in TRK fusion R/R paediatric acute leukaemia (NCT03834961). The gene discussed is NTRK3; the disease is acute lymphoblastic leukemia.